Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Allison, M. Hammond, M. Dowsett, Shannon McKernin, L. Carey, P. Fitzgibbons, D. Hayes, S. Lakhani, M. Chávez-MacGregor, J. Perlmutter, C. Perou, M. Regan, D. Rimm, W. Symmans, E. Torlakovic, E. Torlakovic, Leticia Varella, Giuseppe Viale, G. Viale, T. Weisberg, L. McShane, A. Wolff (2020)
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.Archives of pathology & laboratory medicine
A. Renshaw (2014)
Rosen’s Breast Pathology, 4th EditionAdvances in Anatomic Pathology, 21
Hammond (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)Arch Pathol Lab Med, 1347
K. Allison, M. Hammond, M. Dowsett, Shannon McKernin, L. Carey, P. Fitzgibbons, D. Hayes, S. Lakhani, M. Chávez-MacGregor, J. Perlmutter, C. Perou, M. Regan, D. Rimm, W. Symmans, E. Torlakovic, E. Torlakovic, Leticia Varella, G. Viale, G. Viale, T. Weisberg, L. McShane, A. Wolff (2020)
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
F. Geyer, F. Pareja, B. Weigelt, E. Rakha, I. Ellis, S. Schnitt, J. Reis-Filho (2017)
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.The American journal of pathology, 187 10
A. Landmann, Daniel Farrugia, Li Zhu, E. Diego, Ronald Johnson, A. Soran, D. Dabbs, B. Clark, S. Puhalla, R. Jankowitz, A. Brufsky, G. Ahrendt, P. McAuliffe, R. Bhargava (2018)
Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?American Journal of Clinical Pathology, 150
(2020)
Facts: Female Breast Cancer
M. Yi, L. Huo, K. Koenig, E. Mittendorf, F. Meric-Bernstam, H. Kuerer, I. Bedrosian, A. Buzdar, W. Symmans, J. Crow, M. Bender, Ruchita Shah, G. Hortobagyi, K. Hunt (2014)
Which threshold for ER positivity? a retrospective study based on 9639 patients.Annals of oncology : official journal of the European Society for Medical Oncology, 25 5
C. Davies, Jon Godwin, R. Gray, M. Clarke, D. Cutter, S. Darby, P. Mcgale, Huade Pan, Carolyn Taylor, Y. Wang, M. Dowsett, J. Ingle, R. Peto (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet, 378
D. Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, J. Wittliff (2010)
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Journal of oncology practice, 6 4
H. Gulbahce, C. Blair, C. Sweeney, M. Salama (2017)
Quantification of Estrogen Receptor Expression in Normal Breast Tissue in Postmenopausal Women With Breast Cancer and Association With Tumor SubtypesApplied Immunohistochemistry & Molecular Morphology, 25
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of pathology & laboratory medicine, 134 6
K. Raghav, L. Hernandez-Aya, X. Lei, M. Chávez-MacGregor, F. Meric-Bernstam, T. Buchholz, A. Sahin, K. Do, G. Hortobagyi, A. González-Angulo (2012)
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancersCancer, 118
A. Balduzzi, V. Bagnardi, N. Rotmensz, S. Dellapasqua, E. Montagna, A. Cardillo, G. Viale, P. Veronesi, M. Intra, A. Luini, G. Pruneri, G. Mastropasqua, A. Goldhirsch, M. Colleoni (2014)
Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.Clinical breast cancer, 14 4
Takayuki Iwamoto, Takayuki Iwamoto, D. Booser, V. Valero, J. Murray, K. Koenig, F. Esteva, N. Ueno, Jie Zhang, W. Shi, Y. Qi, J. Matsuoka, Elliana Yang, G. Hortobagyi, C. Hatzis, W. Symmans, L. Pusztai (2012)
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 7
J. Jacquemier, J. Hassoun, M. Torrente, P. Martin (1990)
Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages — Immunohistochemical study of 107 casesBreast Cancer Research and Treatment, 15
M. Hammond, D. Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, N. Goldstein, M. Hayes, D. Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, A. Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).Archives of pathology & laboratory medicine, 134 7
Hammond (2010)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol, 2816
L. Turnbull, G. Ryall, R. Bakhshi, N. Rawson, J. Gazet, C. Nolan, R. Coombes (2006)
Breast Estrogen and Progesterone Receptors in the Normal Female Updated Version
Ricketts (1991)
Estrogen and progesterone receptors in the normal female breastCancer Res, 517
K. Siziopikou (2009)
Rosen's Breast Pathology
L. Dunnwald, M. Rossing, Christopher Li (2007)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patientsBreast Cancer Research, 9
Emily Reisenbichler, S. Lester, A. Richardson, D. Dillon, A. Ly, J. Brock (2013)
Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification.American journal of clinical pathology, 140 4
G. Netto, J. Cheek, N. Zachariah, J. Romer, C. Lee, R. Schoenfeld, Z. Chakmakjian (1990)
Steroid receptors in benign mastectomy tissue.American journal of clinical pathology, 94 1
O. Petersen, P. Høyer, B. Deurs (1987)
Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue.Cancer research, 47 21
S. Khan, M. Rogers, K. Khurana, M. Meguid, P. Numann (1998)
Estrogen receptor expression in benign breast epithelium and breast cancer risk.Journal of the National Cancer Institute, 90 1
The new ASCO/CAP guidelines on hormone receptor testing in breast cancer recommends standard operating procedures (SOPs) established to confirm or adjudicate estrogen receptor (ER) results with weak or ≤10% staining, and the status of internal controls (ICs) reported for cases with 0% to 10% staining. The aim of this study is to determine the frequency of ER testing with weak or ≤10% staining that may require additional steps following SOPs and to identify any correlation between hormone receptor status of the tumor and the likelihood of finding IC. Breast cancer cases between January 2014 and April 2019 were included to identify negative, low-positive and weak-positive cases. The presence/absence of IC was correlated to tumor type. Following ASCO/CAP guidelines, 29.8% of cases (374/1261) will need additional steps to confirm/adjudicate results due to negative, low, or weak positive ER status. The probability of finding IC is ~50% lower in cases of ER and progesterone receptor (PgR) negative tumors. Repeat testing may be warranted in 13.1% (92/700) of all cases due to lack of IC. In conclusion, the new ASCO/CAP guidelines recommend laboratories to establish and follow SOP to confirm or adjudicate ER results for about 30% of the cases before reporting hormone receptors status. Over 40% of cases with <10% tumor ER positivity lacked IC that may need a comment per the guidelines indicating a repeat testing may be warranted. However, the presence/absence of IC may be related to the subtype of breast cancer and should not necessarily bring into question the validity of the test.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Dec 9, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.